Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

Zepbound (tirzepatide ... your doctor will increase your dosage to 5 mg injected once per week for 4 weeks. If needed, your doctor may increase your weekly dose in increments of 2.5 mg until ...

With pharmaceutical GLP-1 drugs like semaglutide in high demand, Metamorphx offers a plant-based alternative designed to ...

The NDA is supported by data from the phase 3 OASIS 4 trial (ClinicalTrials.gov Identifier: NCT05564117), a 64-week study that included a 12-week dose escalation and a 7-week off-treatment follow ...

Neoadjuvant PD-1 blockade with dostarlimab enables nonoperative management strategy for large proportion of patients. HealthDay News — A neoadjuvant programmed cell death 1 (PD-1) blockade ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

Between 2021 and 2023, 800 randomly selected participants across 37 countries received once-weekly injections of either semaglutide or a placebo, the press release stated. More than half had type ...

Mortgage rates fell to a three-week low, and with positive trends in home prices and inventory, the market is gradually moving in favor of buyers. The average rate on a 30-year fixed-rate mortgage ...

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks Consensus Estimate of $3.52 per share. Earnings rose 29% year over year.

Eli Lilly and Company (LLY) reported its first-quarter results for 2025, revealing a revenue increase of 45% compared to the same period last year, driven by strong sales of key products.